Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 1/20 | 0.49 |
| ▸ | NTRK1 | P04629 | 17/20 | 0.48 |
| ▸ | NTRK2 | Q16620 | 3/20 | 0.48 |
| ▸ | NTRK3 | Q16288 | 2/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.47 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.41 |
| ▸ | RET | P07949 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4086378 | 0.78 | NTRK1 (0.52) | NTRK1NTRK2NTRK3KCNH2PDPK1 | |
| SCHEMBL4084830 | 0.77 | NTRK1 (0.61) | PDGFRBNTRK1NTRK2NTRK3KCNH2 | |
| SCHEMBL5316496 | 0.77 | PDGFRB (0.43) | PDGFRBNTRK1NTRK2NTRK3KCNH2 | |
| SCHEMBL4079535 | 0.73 | PDPK1 (0.45) | PDGFRBNTRK1NTRK2NTRK3KCNH2 | |
| SCHEMBL15636335 | 0.73 | NTRK1 (0.65) | NTRK1 | |
| SCHEMBL4081460 | 0.71 | PDGFRB (0.61) | PDGFRBNTRK1NTRK2NTRK3KCNH2 | |
| SCHEMBL4080547 | 0.71 | PDGFRB (0.78) | PDGFRBNTRK1NTRK2NTRK3KCNH2 | |
| SCHEMBL1942227 | 0.71 | TSHR (0.43) | PDGFRBPDPK1KDR | |
| SCHEMBL4081058 | 0.71 | NTRK1 (0.74) | PDGFRBNTRK1NTRK2NTRK3KCNH2 | |
| SCHEMBL4086121 | 0.71 | PDGFRB (0.42) | PDGFRBNTRK1NTRK2NTRK3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7595325-B2 | Substituted pyrrolo[2,3-d]pyrimidine derivatives useful in cancer treatment | PFIZER INC. (US) | 2009-09-29 | — | — | US | disclosed |
| EP-1773836-A1 | PYRROLOPYRIMIDINE DERIVATIVES USEFUL IN CANCER TREATMENT | Pfizer Products Inc. (US) | 2007-04-18 | — | — | EP | disclosed |
| US-20060035912-A1 | Pyrrolopyrimidine derivatives useful in cancer treatment | PFIZER INC | 2006-02-16 | — | — | US | disclosed |
| WO-2005116035-A1 | PYRROLOPYRIMIDINE DERIVATIVES USEFUL IN CANCER TREATMENT | PFIZER PRODUCTS INC. (US) | 2005-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060035912-A1 | Pyrrolopyrimidine derivatives useful in cancer treatment | TP53, DPYD, CCNT1 | PDGFRB 2700/4885NTRK1 3916/4885NTRK2 4246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.